Search results
Some drugmakers to cap cost of asthma inhalers at $35 a month
NBC Universal via AOL· 5 days agoStarting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price...
AstraZeneca shares target raised by Argus on new drug approvals By Investing.com
Investing.com· 7 days agoOn Thursday, AstraZeneca PLC (NASDAQ:LON:AZN) shares received an updated price target from a market...
Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca By...
Investing.com· 6 days agoIn their first quarter 2024 earnings call, Cellectis, a biopharmaceutical company, presented a...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks· 3 days agoFree Report) closed the most recent trading day at $78.99, moving +1.24% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.11%. Coming into today, shares of ...
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
BioPharma Dive via Yahoo Finance· 4 days agoAstraZeneca’s immunotherapy Imfinzi helped people in the early stages of a type of lung cancer live...
AstraZeneca (NASDAQ:AZN) Now Covered by Analysts at The Goldman Sachs Group
ETF DAILY NEWS· 6 days agoThe Goldman Sachs Group assumed coverage on shares of AstraZeneca (NASDAQ:AZN – Free Report) in a research report report published on Thursday morning, Marketbeat Ratings ...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 6 days agolongest-serving chief executive, Pascal Soriot, has no plans to step down for now as the company...
Parallel Advisors LLC Sells 169 Shares of AstraZeneca PLC (NASDAQ:AZN)
ETF DAILY NEWS· 7 days agoParallel Advisors LLC reduced its stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 1.2% during the fourth quarter, according to the company in its most recent 13F filing ...
Compugen hits milestone with AstraZeneca cancer trial By Investing.com
Investing.com· 6 days agoThe trial is a crucial step in evaluating the drug as a first-line treatment for a specific type of...
Cancer Drugs: Deals and Licensing for Antibody-Drug Conjugates
The National Law Review· 5 hours agoAntibody-drug conjugates (ADCs) are a promising class of cancer treatments with an accelerating...